Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeronGERN -0.67%25 3-Year EBITDA Growth Rate is 40.50% as of Jun. 2026, which is 1346% above its 10-year median of 2.80. GuruFocus rates GERN with a GF Score™ of 25/100. The stock has 4 warning signs investors should review. Among 1,127 Biotechnology companies, Geron ranks better than 78.88% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 40.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 19.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Geron was 40.50% per year. The lowest was -30.60% per year. And the median was 2.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Geron 3-Year EBITDA Growth Rate Related Terms
GERN vs ARDX, DSGN, ANNX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Geron's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geron 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geron's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Geron's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 40.50% mean?
Geron (GERN) has a 3-Year EBITDA Growth Rate of 40.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Geron and its competitors. This is 1346% above median its historical median of 2.80. According to the industry distribution chart, Geron ranks #238 out of 1127 companies in the Biotechnology industry, placing it in the top 21.1%.
Is Geron's 3-Year EBITDA Growth Rate too high?
Geron's current 3-Year EBITDA Growth Rate of 40.50% is 1346% above median its 10-year median of 2.80. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.70. Geron's value of 40.50% is 175.5% above this industry median. Based on the distribution chart, Geron ranks #238 out of 1127 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Geron has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Geron's 3-Year EBITDA Growth Rate compare to ARDX and DSGN?
According to the Biotechnology industry distribution chart, Geron ranks #238 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Geron in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.70. Geron's value of 40.50% is 175.5% above this benchmark. While the company's 10-year median is 2.80 vs. the industry median of 14.70, Geron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.70, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Geron's current 3-Year EBITDA Growth Rate of 40.50% is 175.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Geron and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Geron's current 3-Year EBITDA Growth Rate is 40.50%, which is 1346% above median its own 10-year median of 2.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Geron (GERN) has a current 3-Year EBITDA Growth Rate of 40.50%. The current 3-Year EBITDA Growth Rate is 40.50%, which is 1346% above median its 10-year median of 2.80 and 175.5% above the Biotechnology industry median of 14.70. Geron's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Geron (GERN), the current 3-Year EBITDA Growth Rate is 40.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
25GF Score
Get the complete analysis for GERN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GERN has been successfully added to your 
